

## **CURRICULUM VITAE**

**Enrico Derenzini, MD, PhD**

Nato a Bologna il 16/03/1978

Residente in Via Previati 3, 40139, Bologna, Italia

## **POSIZIONE LAVORATIVA ATTUALE**

**Da Febbraio 2016, Medico Ematologo (contratto libero-professionale) presso Istituto Europeo di Oncologia, Milano, Italia.** Area di interesse: Gestione clinica delle sindromi linfoproliferative, Ricerca traslazionale nel campo delle sindromi linfoproliferative.

**Dal 2019 docente della European School of Molecular Medicine (SEMM), Istituto Europeo di Oncologia, Milano.**

**Dal 2020 Ricercatore Universitario c/o Dipartimento di Scienze della Salute, Università di Milano**

## **TITOLI DI STUDIO ED ESPERIENZE PROFESSIONALI**

**30 Ottobre 2003: Laurea in Medicina e Chirurgia con 110/110 e lode, presso Università di Bologna.**

**2004: Abilitazione all'esercizio della professione medica**

**8 Luglio 2004: Iscrizione all'albo Provinciale dei Medici-Chirurghi di Bologna. N° 0000014996**

**2001-2003 studente interno presso l'unità di Oncologia (Istituto di Ematologia ed Oncologia Medica L.A. Seragnoli), Ospedale S.Orsola-Malpighi, Bologna.**

Direttore: Prof. G. Biasco

2003-2007 Specialita' in Oncologia Medica, presso Scuola di Specializzazione in Oncologia Medica, Universita' di Bologna, Ospedale S.Orsola, Bologna

Direttore: Prof. G. Biasco

4 Dicembre 2007: **Conseguimento del diploma di specialita' in Oncologia con lode**, Universita' di Bologna.

Direttore: Prof. G. Biasco

2008-2012 Specialita' in Ematologia presso Scuola di Specializzazione in Ematologia, Universita' di Bologna, Istituto di Ematologia ed Oncologia Medica L.A. Seragnoli, Ospedale S.Orsola, Bologna.

Direttore: Prof. M. Bacarani

26 Marzo 2012 **Conseguimento del diploma di specialita' in Ematologia con lode**, Universita' di Bologna.

Direttore: Prof. P.L. Zinzani

22 Gennaio 2015 **Conseguimento del Dottorato di Ricerca in Scienze Biomediche** Ciclo 27, Settore concorsuale 06/A4, settore scientifico-disciplinare MED/08. Tesi intitolata: "The constitutive activation of the DNA damage response pathway is a novel therapeutic target in aggressive B-cell lymphoma".

Relatore: Prof. Stefano Pileri

Coordinatore Dottorato: Prof. Lucio Ildebrando Cocco

6 Aprile 2017- **Conseguimento dell' Abilitazione Scientifica Nazionale a Professore Universitario di II fascia**, Settore concorsuale 06/D3. Malattie del sangue, oncologia e reumatologia.

## **ESPERIENZE DI RICERCA PRESSO ISTITUZIONI ESTERE**

13 Luglio 2009- 26 Gennaio 2011

**Post-Doctoral Fellow** nel Lymphoma/Myeloma Department, University of Texas **MD Anderson Cancer Center**, Houston, Texas. Chief: Prof. Anas Younes.

1 Giugno 2013- 1 Settembre 2015

**Research Fellow** nel Department of Medicine, Anas Younes Laboratory, **Memorial Sloan Kettering Cancer**, New York. Chief: Prof. Anas Younes.

## **ATTIVITA' EDITORIALE E DI REVISORE PER RIVISTE INTERNAZIONALI CON IMPACT FACTOR**

**Abstract Reviewer 2019 ASH meeting (Orlando, USA)**

**Abstract Reviewer, Congress Officer, Chair 2014 ESMO congress (Madrid, Spain)**

**Abstract Reviewer 2013 ASH meeting (New Orleans, USA)**

**Revisore per riviste internazionali nel campo dell'Ematologia:** Blood, Clinical Cancer Research, Haematologica, British Journal Haematology, European Journal of Haematology, Future Oncology, Clinical Lymphoma Myeloma and Leukemia, Leukemia and Lymphoma, PLOS ONE, Oncotarget.

**Associate Editor** per European Journal of Haematology

## **PRESENTAZIONI NELL'AMBITO DI CONFERENZE E CONGRESSI NAZIONALI ED INTERNAZIONALI**

**Oral presentation 2018 ASH meeting in San Diego:** Integration of Nanostring Profiling and Functional Characterization of Oxidative and Replicative Stress Biomarkers Identifies Poor Prognosis MYC/BCL-2 Positive Diffuse Large B-Cell Lymphoma Subsets, Providing Opportunities for Precision Therapies. Abstr 676.

**Oral presentation 2018 EBMT meeting in Lisbona:** Immune checkpoints activation dictates outcome after allogeneic transplant in lymphoma. Abstr OSI-17.

**Oral presentation 2016 ASH meeting in San Diego:** MYC-dependent PI3K and MCL-1 feedbacks attenuate BET inhibitors activity in Diffuse Large B-cell Lymphoma. Session 625. Abstr 294.

**Invited Discussant abstracts 9440, 9450 and 9460, ESMO meeting 2014 in Madrid:** 29 Settembre 2014.

**Invited Speaker: “ I Linfomi a Cellule T Periferiche nella Revised WHO Classification. Dalla diagnostica alle terapie con anticorpi anti-CD30”,** Genova 22-23 Novembre 2018.

**Invited Speaker:” Liquid Biopsy in Hematological Malignancies”.** Università di Padova 25 Gennaio 2018

**Invited speaker 2015 SIE Congress in Florence: Meet the Expert “Come gestisco le istiocitosi”.** Firenze, 5 Ottobre 2015.

**Invited Speaker: Discutiamone Insieme SIES 2012 Session: Linfoma di Hodgkin: Conoscere di piu’ la biologia per migliorare la terapia: Title: “Target biomolecolari”.** Firenze 29 Marzo 2012.

**Invited Speaker: SIE/SIES sponsored event: Linfoma di Hodgkin: Siamo alla svolta finale? Title:” La target therapy nel linfoma di Hodgkin”.** Pozzuoli 9-10 Marzo 2012.

## **PROGETTI DI RICERCA**

AIRC 5 X 1000 2018 (Molecular bases of disease dissemination in lymphoid malignancies to optimize curative therapeutic strategies): Componente del progetto.

## **BREVETTI**

**Brevetto italiano n. RM2014A000215** per l’invenzione di una nuova linea cellulare di linfoma di Burkitt “RALE051”. Data deposito: 29 Aprile 2014. Data di pubblicazione: 30 Ottobre 2015. Data di concessione: 26 Agosto 2016.

## **ATTIVITA’ DIDATTICA**

CORRELATORE DI TESI DI LAUREA MAGISTRALE IN BIOLOGIA SPERIMENTALE ED APPLICATA

CORRELATORE DI TESI DI LAUREA IN MEDICINA E CHIRURGIA

**LINGUE STRANIERE: Inglese, Francese.**

## **PUBBLICAZIONI**

**N=67**

**H index: 21 (Scopus, Luglio 2019)**

## Numero totale di citazioni: 1409 (Scopus, Luglio 2019)

- 1- Sapienza MR\*, Pileri A\*, **Derenzini E\***, Melle F, Motta G, Fiori S, Calleri A, Pimpinelli N, Tabanelli V, Pileri S. Blastic Plasmacytoid Dendritic Cell Neoplasm: State of the Art and Prospects. *Cancers (Basel)*. 2019 Apr 28;11(5). pii: E595. \* Equal contribution.
- 2- **Derenzini E**, Risso A, Ruella M, Spatola T, Milone G, Pioltelli P, Iori AP, Santarone S, Bosi A, Rambaldi A, Bacigalupo AP, Arcese W, Tarella C. Influence of Donor and Recipient Gender on Telomere Maintenance after Umbilical Cord Blood Cell Transplantation: A Study by the Gruppo Italiano Trapianto Di Midollo Osseo. *Biol Blood Marrow Transplant*. 2019;25(7):1387-1394.
- 3- Pileri SA, **Derenzini E**, Melle F, Motta G, Calleri A, Antoniotti P, Maltoni V, Spagnolo S, Fiori S, Tabanelli V, Fabbri M. Dissecting diffuse large B-cell lymphomas of the "not otherwise specified" type: the impact of molecular techniques. *F1000Res*. 2018 Dec 21;7. pii: F1000 Faculty Rev-1966. doi:10.12688/f1000research.16755.1.
- 4- Ciavarella S, Vegliante MC, Fabbri M, De Summa S, Melle F, Motta G, De Iulius V, Opinto G, Enjuanes A, Rega S, Gulino A, Agostinelli C, Scattone A, Tommasi S, Mangia A, Mele F, Simone G, Zito AF, Ingravallo G, Vitolo U, Chiappella A, Tarella C, Gianni AM, Rambaldi A, Zinzani PL, Casadei B, **Derenzini E**, Loseto G, Pileri A, Tabanelli V, Fiori S, Rivas-Delgado A, López-Guillermo A, Venesio T, Sapino A, Campo E, Tripodo C, Guarini A, Pileri SA. Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue. *Ann Oncol*. 2018 Dec 1;29(12):2363-2370..
- 5- **Derenzini E**, Mondello P, Erazo T, Portelinha A, Liu Y, Scallion M, Asgari Z, Philip J, Hilden P, Valli D, Rossi A, Djaballah H, Ouerfelli O, de Stanchina E, Seshan VE, Hendrickson RC, Younes A. BET Inhibition-Induced GSK3 $\beta$  Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors. *Cell Rep*. 2018;24(8):2155-2166.
- 6- **Derenzini E**, Agostinelli C, Rossi A, Rossi M, Scellato F, Melle F, Motta G, Fabbri M, Diop F, Kodipad AA, Chiappella A, Vitolo U, Gaidano G, Tarella C, Pileri S. Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma. *Br J Haematol*. 2019 Apr;185(2):330-334.

- 7- **Derenzini E**, Rossi A, Treré D. Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why. *J Hematol Oncol*. 2018;11(1):75.
- 8- L'Abbate A, Iacobucci I, Lonoce A, Turchiano A, Ficarra E, Paciello G, Cattina F, Ferrari A, Imbrogno E, Agostinelli C, Zinzani P, Martinelli G, **Derenzini E**, Storlazzi CT. RALE051: a novel established cell line of sporadic Burkitt lymphoma. *Leuk Lymphoma*. 2018;59(5):1252-1255.
- 9- Mondello P, **Derenzini E**, Asgari Z, Philip J, Brea EJ, Seshan V, Hendrickson RC, de Stanchina E, Scheinberg DA, Younes A. Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma. *Oncotarget*. 2017;8(8):14017-14028.
- 10- Di Rorà AG, Iacobucci I, Imbrogno E, Papayannidis C, **Derenzini E**, Ferrari A, Guadagnuolo V, Robustelli V, Parisi S, Sartor C, Abbenante MC, Paolini S, Martinelli G. Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia. *Oncotarget*. 2016 7(33):53377-53391.
- 11- Shono Y, Tuckett AZ, Liou HC, Doubrovina E, **Derenzini E**, Ouk S, Tsai JJ, Smith OM, Levy ER, Kreines FM, Ziegler CG, Scallion MI, Doubrovin M, Heller G, Younes A, O'Reilly RJ, van den Brink MR, Zakrzewski JL. Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF- $\kappa$ B-Controlled Oxidative Stress Responses. *Cancer Res*. 2016 Jan 15;76(2):377-89.
- 12- **Derenzini E**, Iacobucci I, Agostinelli C, Imbrogno E, Storlazzi CT, L Abbate A, Casadei B, Ferrari A, Di Rora AG, Martinelli G, Pileri S, Zinzani PL. Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma. *Exp Hematol Oncol*. 2015 Aug 27;4:24.
- 13- Iacobucci I, Di Rorà AG, Falzacappa MV, Agostinelli C, **Derenzini E**, Ferrari A, Papayannidis C, Lonetti A, Righi S, Imbrogno E, Pomella S, Venturi C, Guadagnuolo V, Cattina F, Ottaviani E, Abbenante MC, Vitale A, Elia L, Russo D, Zinzani PL, Pileri S, Pelicci PG, Martinelli G. *J Hematol Oncol*. 2015 Nov 5;8(1):125.
- 14- **Derenzini E**, Stefoni V, Pellegrini C, Gandolfi L, Broccoli A, Casadei B, Quirini F, Argnani L, Tonialini L, Zinzani PL. High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience. *BMC Cancer*. 2015 Nov 9;15:879.
- 15- Trino S, Iacobucci I, Erriquez D, Laurenzana I, Luca L, Ferrari A, Rorà AG, Papayannidis C, **Derenzini E**, Simonetti G, Lonetti A, Venturi C, Cattina F, Ottaviani

- E, Abbenante MC, Russo D, Perini G, Musto P, Martinelli G. Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients. *Oncotarget*. 2016 Mar 15;7(11):12951-61
- 16- **Derenzini E**, Agostinelli C, Imbrogno E, Iacobucci I, Casadei B, Brighenti E, Righi S, Fuligni F, Ghelli Luserna Di Rorà A, Ferrari A, Martinelli G, Pileri S, Zinzani PL. Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. *Oncotarget*. 2015 Mar 30;6(9):6553-69.
- 17- Mondello P, Pitini V, Arrigo C, **Derenzini E**, Mian M. 90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment. *Anticancer Res*. 2014 Sep;34(9):5121-5.
- 18- Pellegrini C, Argnani L, Broccoli A, Stefoni V, **Derenzini E**, Gandolfi L, Casadei B, Maglie R, Pileri S, Zinzani PL. Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. *Oncologist*. 2014 Jul;19(7):746-50.
- 19- **Derenzini E**, Casadei B, Broccoli A, Gandolfi L, Pellegrini C, Zinzani PL. Sequential therapy with alternating short courses of r-chop (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and r-fm (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. *Br J Haematol*. 2014 Aug;166(4):625-8.
- 20- **Derenzini E**, Zinzani PL, Cheson BD. Bendamustine: role and evidence in lymphoma therapy, an overview. *Leuk Lymphoma*. 2014 Jul;55(7):1471-8.
- 21- **Derenzini E**, Stefoni V, Maglie R, Casadei B, Pellegrini C, Broccoli A, Stefani G, Fanti S, Motta MR, Narducci R, Argnani L, Zinzani PL. Collection of hematopoietic stem cells after previous radioimmunotherapy is feasible and does not impair engraftment after autologous stem cell transplantation in follicular lymphoma. *Biol Blood Marrow Transplant*. 2013 Dec;19(12):1695-701.
- 22- Zinzani PL, **Derenzini E**, Pellegrini C, Celli M, Broccoli A, Argnani L. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. *Br J Haematol*. 2013 Dec;163(5):681-3.
- 23- Brandi G, **Derenzini E**, Falcone A, Masi G, Loupakis F, Pietrabissa A, Pinna AD, Ercolani G, Pantaleo MA, Di Girolamo S, Grazi GL, de Rosa F, Biasco G. Adjuvant

systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. *Clin Colorectal Cancer*. 2013 Sep;12(3):188-94.

- 24- Gentile G, Broccoli A, Brunocilla E, Schiavina R, Borghesi M, Romagnoli D, Bianchi L, **Derenzini E**, Agostinelli C, Franceschelli A, Colombo F, Zinzani PL. An isolated penile mass in a young adult turned out to be a primary marginal zone lymphoma of the penis. A case report and a review of literature. *Anticancer Res*. 2013 Jun;33(6):2639-42.
- 25- Broccoli A, **Derenzini E**, Pellegrini C, Narducci R, Stefani G, Casadei B, Argnani L, Zinzani PL. Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. *Clin Lymphoma Myeloma Leuk*. 2013 Aug;13(4):493-5.
- 26- Zinzani PL, Viviani S, Anastasia A, Vitolo U, Luminari S, Zaja F, Corradini P, Spina M, Brusamolino E, Gianni AM, Santoro A, Botto B, **Derenzini E**, Pellegrini C, Argnani L. Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. *Haematologica*. 2013 Aug;98(8):1232-6.
- 27- Zinzani PL, Pellegrini C, **Derenzini E**, Argnani L, Pileri S. Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. *Hematol Oncol*. 2013 Apr 26. doi: 10.1002/hon.2049.
- 28- **Derenzini E**, Younes A. Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib. *Expert Opin Investig Drugs*. 2013;22(6):775-85.
- 29- Pastorelli F, **Derenzini E**, Plasmati R, Pellegrini C, Broccoli A, Casadei B, Argnani L, Salvi F, Pileri S, Zinzani PL. Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. *Leuk Lymphoma*. 2013 Oct;54(10):2318-21.
- 30- **Derenzini E**, Casadei B, Pellegrini C, Argnani L, Pileri S, Zinzani PL. Non-Hodgkin Lymphomas Presenting as Soft Tissue Masses: A Single Center Experience and Meta-analysis of the Published Series. *Clin Lymphoma Myeloma Leuk*. 2012 Dec 12. pii: S2152-2650(12)00253-4.
- 31- Zinzani PL, Pellegrini C, Gandolfi L, Casadei B, **Derenzini E**, Broccoli A, Quirini F, Argnani L, Pileri S, Celli M, Fanti S, Poletti V, Stefani V, Baccarani M. Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. *Hematol Oncol*. 2013 Dec;31(4):183-8.



- 32- Broccoli A, Stanzani M, Bandini G, Bonifazi F, Stefoni V, Pellegrini C, **Derenzini E**, Gandolfi L, Quirini F, Argnani L, Tschon M, Casadei B, Baccarani M, Zinzani PL. Allograft in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients. *Leuk Lymphoma*. 2013 Aug;54(8):1791-3.
- 33- Zinzani PL, Pellegrini C, Merla E, Ballerini F, Fabbri A, Guarini A, Pavone V, Quintini G, Puccini B, Vigliotti ML, Stefoni V, **Derenzini E**, Broccoli A, Gandolfi L, Quirini F, Casadei B, Argnani L, Baccarani M. Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study. *Hematol Oncol*. 2013 Dec;31(4):179-82.
- 34- Lemoine M, **Derenzini E**, Buglio D, Medeiros LJ, Davis RE, Zhang J, Ji Y, Younes A. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. *Blood*. 2012 Apr 26;119(17):4017-25.
- 35- Zinzani PL, **Derenzini E**, Pellegrini C, Rigacci L, Fabbri A, Gandolfi L, Argnani L, Casadei B, Pulsoni A, Gobbi M, Perotti A, Zaccaria A, Voso MT, Cabras MG, De Renzo A. Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). *Ann Oncol*. 2012 Mar;23(3):805-7+
- 36- **Derenzini E**, Lemoine M, Buglio D, Katayama H, Ji Y, Davis RE, Sen S and Younes A. The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin Lymphoma. *Blood Cancer Journal* 2011, 1(12): e46.
- 37- Brandi G, Biasco G, Mirarchi MG, Golfieri R, Di Paolo A, Borghi A, Fanello S, **Derenzini E**, Agostini V, Giampalma E, Cappelli A, Pini P, Costantini S, Danesi R, Bolondi L, Piscaglia F. A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. *Dig Liver Dis*. 2011; 43(12):1015-21.
- 38- Zinzani PL, Pellegrini C, Gandolfi L, Stefoni V, Quirini F, **Derenzini E**, Broccoli A, Argnani L, Pileri S, Baccarani M. Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial. *Clin Lymphoma Myeloma Leuk*. 2011 Dec;11(6):462-6.
- 39- Pellegrini C, Gandolfi L, Quirini F, Ruggieri P, Stefoni V, **Derenzini E**, Broccoli A, Argnani L, Pileri S, Mercuri M, Baccarani M, Zinzani PL. Primary Bone Lymphoma: Evaluation of Chemoimmunotherapy as Front-line Treatment in 21 Patients. *Clin Lymphoma Myeloma Leuk*. 2011;11(4):321-5.

- 40- Jóna A, Khaskhely N, Buglio D, Shafer JA, **Derenzini E**, Bollard CM, Medeiros LJ, Illés A, Ji Y, Younes A. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. *Exp Hematol.* 2011 Oct;39(10):1007-1017.e1.
- 41- Lopci E, Burnelli R, Guerra L, Cistaro A, Piccardo A, Zucchetta P, **Derenzini E**, Todesco A, Garaventa A, Schumacher F, Farruggia P, Buffardi S, Sala A, Casale F, Indolfi P, Biondi S, Pession A, Fanti S. Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin's disease. *Eur J Nucl Med Mol Imaging.* 2011 Sep;38(9):1620-7.
- 42- **Derenzini E**, Younes A. Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances. *Genome Med.* 2011 Apr 28;3(4):26.
- 43- Zinzani PL, Tani M, Pulsoni A, De Renzo A, Stefoni V, Broccoli A, Montini GC, Fina M, Pellegrini C, Gandolfi L, Cavalieri E, Torelli F, Scopinaro F, Argnani L, Quirini F, **Derenzini E**, Rossi M, Pileri S, Fanti S, Baccharani M. A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. *Ann Oncol.* 2012 Feb;23(2):415-20.
- 44- Zinzani PL, Pellegrini C, Broccoli A, Stefoni V, Gandolfi L, Quirini F, Argnani L, Berti E, **Derenzini E**, Pileri S, Baccharani M. Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. *Leuk Lymphoma.* 2011 Aug;52(8):1585-8.
- 45- Zinzani PL, Gandolfi L, Broccoli A, Argnani L, Fanti S, Pellegrini C, Stefoni V, **Derenzini E**, Quirini F, Baccharani M. Midtreatment (18) F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. *Cancer.* 2011 Mar 1;117(5):1010-8. doi: 10.1002/cncr.25579.
- 46- Zinzani PL, Gandolfi L, Stefoni V, Fanti S, Fina M, Pellegrini C, Montini GC, **Derenzini E**, Broccoli A, Argnani L, Pileri S, Baccharani M. Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. *Clin Lymphoma Myeloma Leuk.* 2010 Aug 1;10(4):258-61.
- 47- Zinzani PL, Pellegrini C, Stefoni V, **Derenzini E**, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccharani M. Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. *Cancer.* 2010 Oct 15;116(20):4788-92.
- 48- Zinzani PL, Rossi G, Franceschetti S, Botto B, Di Rocco A, Cabras MG, Petti MC, Stefoni V, Broccoli A, Fanti S, Pellegrini C, Montini GC, Gandolfi L, **Derenzini E**,

- Argnani L, Fina M, Tucci A, Bottelli C, Pileri S, Baccarani M. Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. *Clin Cancer Res.* 2010 Aug 1;16(15):3998-4004.
- 49- Lopci E, Santi I, **Derenzini E**, Fonti C, Savelli G, Bertagna F, Bellò M, Botto B, Huglo D, Morschhauser F, Zinzani P, Fanti S. FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. *Ann Oncol.* 2010 Sep;21(9):1877-83.
- 50- Zinzani PL, Venturini F, Stefoni V, Fina M, Pellegrini C, **Derenzini E**, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. *Ann Oncol.* 2010 Apr;21(4):860-3.
- 51- **Derenzini E**, Fina MP, Stefoni V, Pellegrini C, Venturini F, Broccoli A, Gandolfi L, Pileri S, Fanti S, Lopci E, Castellucci P, Agostinelli C, Baccarani M, Zinzani PL. MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. *Ann Oncol.* 2010 Jun;21(6):1173-8.
- 52- Papayannidis C, **Derenzini E**, Iacobucci I, Curti A, Paolini S, Cilloni D, Baccarani M, Martinelli G. Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia. *Am J Hematol.* 2009 Dec;84(12):849-50.
- 53- **Derenzini E**, Stefoni V, Pellegrini C, Fina MP, Broccoli A, Venturini F, Gandolfi L, Pileri SA, Martelli M, Petti MC, Perrotti A, De Renzo A, Zaja F, Baccarani M, Zinzani PL. Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomycin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. *Leuk Lymphoma.* 2009 Nov;50(11):1824-9.
- 54- Stefoni V, Broccoli A, Pellegrini C, **Derenzini E**, Fina M, Zinzani PL. CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission. *J Neurooncol.* 2009 Oct;95(1):135-9.
- 55- Palandri F\*, **Derenzini E\***, Ottaviani E, Polverelli N, Catani L, Salmi F, Sabattini E, Bacci F, Zinzani PL, Baccarani M, Vianelli N. Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience. \* Equal contribution. *Leuk Lymphoma.* 2009 Mar;50(3):481-4.

- 56- Zinzani PL, Stefoni V, Tani M, Fanti S, Musuraca G, Castellucci P, Marchi E, Fina M, Ambrosini V, Pellegrini C, Alinari L, **Derenzini E**, Montini G, Broccoli A, Bacci F, Pileri S, Baccarani M. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. *J Clin Oncol*. 2009 Apr 10;27(11):1781-7.
- 57- **Derenzini E**, Musuraca G, Fanti S, Stefoni V, Tani M, Alinari L, Venturini F, Gandolfi L, Baccarani M, Zinzani PL. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. *Cancer*. 2008 Nov 1;113(9):2496-503.
- 58- Zinzani PL, Tani M, Pulsoni A, Gobbi M, Perotti A, De Luca S, Fabbri A, Zaccaria A, Voso MT, Fattori P, Guardigni L, Ronconi S, Cabras MG, Rigacci L, De Renzo A, Marchi E, Stefoni V, Fina M, Pellegrini C, Musuraca G, **Derenzini E**, Pileri S, Fanti S, Piccaluga PP, Baccarani M. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). *Lancet Oncol*. 2008 Apr;9(4):352-8.
- 59- Zinzani PL, Tani M, Fanti S, Stefoni V, Musuraca G, Castellucci P, Marchi E, Farsad M, Fina M, Pellegrini C, Alinari L, **Derenzini E**, de Vivo A, Bacci F, Pileri S, Baccarani M. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. *Ann Oncol*. 2008 Apr;19(4):769-73.
- 60- **Derenzini E**, Paolini S, Martinelli G, Campidelli C, Grazi GL, Calabrese C, Zinzani PL, Baccarani M. Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: a diagnostic and therapeutic challenge. *Leuk Lymphoma*. 2008 Jan;49(1):159-62.
- 61- Zinzani PL, Tani M, Fanti S, Stefoni V, Musuraca G, Vitolo U, Perotti A, Fina M, **Derenzini E**, Baccarani M. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. *Cancer*. 2008 Feb 15;112(4):856-62.
- 62- Zinzani PL, Poletti V, Zompatori M, Tani M, Spaggiari L, Tomassetti S, Broccoli A, **Derenzini E**, Baccarani M. Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma. *Clin Lymphoma Myeloma*. 2007 Nov;7(9):566-72.

- 63- Fina M, Tani M, Stefoni V, Musuraca G, Marchi E, Pellegrini C, Alinari L, **Derenzini E**, Bacci F, Pileri S, Bacarani M, Zinzani PL. VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. *Leuk Lymphoma*. 2007 Nov;48(11):2167-71.
- 64- Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, Pellegrini C, Alinari L, **Derenzini E**, de Vivo A, Sabbatini E, Pileri S, Bacarani M. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. *J Clin Oncol*. 2007 Sep 20;25(27):4293-7.
- 65- Biasco G, **Derenzini E**, Grazi G, Ercolani G, Ravaioli M, Pantaleo MA, Brandi G. Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. *Cancer Treat Rev*. 2006 May;32(3):214-28.
- 66- Biasco G, Di Battista M, **Derenzini E**. Slow evolution of liver metastasis from colon cancer. *Dig Liver Dis*. 2005 Aug;37(8):628-9.
- 67- **Derenzini E**, Di Battista M, Di Marco MC, Dell'Arte S, Astorino M, Bertolini S, Brandi G, Biasco G. [Treatment of colorectal cancer liver metastases]. *Minerva Med*. 2006 Feb;97(1):107-19.

**Collaboratore nell'opera "Corso di Malattie del Sangue e degli Organi Emolinfopoietici"**  
**VI edizione, 2015, Autore S. Tura, edito da Societa' Editrice Esculapio.**  
ISBN: 9788874888849.

**Milano, 1/4/2020**